Aufa S, Ismy J. Sequential Gemcitabine and Docetaxel Versus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer. IJGHR [Internet]. 2026 Sep. 4 [cited 2026 Sep. 4];8(6):89-98. Available from: https://jurnal2.globalhealthsciencegroup.com/index.php/IJGHR/article/view/2572